Federal Capture Intelligence

Research and Development in Biotechnology contractors at the Department of Health and Human Services

Contract actions: October 1, 2021 – July 27, 2026 Updated July 28, 2026 Department of Health and Human Services agency guide NAICS 541711 · Research and Development in Biotechnology
Latest 12 months
-$306.0M
Net obligations · Down $379.0M vs. $73.0M preceding
Prime contractors
8
With positive obligations in the latest 12 months

Market snapshot for Research and Development in Biotechnology at the Department of Health and Human Services

Federal records show $535.9M in net obligations across 676 awards in Research and Development in Biotechnology at the Department of Health and Human Services from Oct 1, 2021 through Jul 27, 2026. This market accounts for 0.38% of $140.6B in agency-wide net prime contract obligations over the period shown. Latest 12-month net obligations moved from $73.0M in net obligations to $306.0M in net deobligations. 2 prime contractors accounted for at least 80% of positive obligations in that latest period.

Fiscal-year activity

FY26 is year-to-date through Jul 27, 2026; earlier years show complete fiscal-year totals.

FY26 year-to-date: −$10.8M versus $91.5M through the same date in FY25 (Not comparable).
Net obligations · complete fiscal yearNet obligations · FY26 YTDContract actions
View fiscal-year data table
Fiscal yearNet obligationsContract actionsCoverage
FY2022$123.2M641Complete
FY2023$541.2M416Complete
FY2024$85.9M358Complete
FY2025−$203.7M183Complete
FY2026−$10.8M58YTD through Jul 27, 2026

Market at a glance

All reported prime contract awards
All-period net obligations
$535.9M
676 awards · 211 prime contractors
Latest 12-month movement
Not comparable
−$306.0M vs. $73.0M
Leading eight prime share
100.0%
Share held by the eight leading prime contractors in the latest 12 months
View agency share, denominators, and set-aside reporting
Agency context
0.38% of $140.6B in agency-wide net obligations.
Set-aside share when reported
5.5% of 309 awards with reported set-aside status.
Set-aside reporting
17 set aside · 292 no set-aside · 367 not reported

What changed in the last 12 months?

Jul 28, 2025–Jul 27, 2026, compared with Jul 28, 2024–Jul 27, 2025.

Competitive shifts

REGENERON PHARMACEUTICALS INC recorded the largest net deobligation
$0→−$332.0M−$332.0M
The contractor now is unranked by positive obligations, based on 3 reported actions.
THE EMMES COMPANY, LLC gained the most market share
5.9%→8.8%+2.9 percentage points
The contractor now ranks #3 by positive obligations, based on 5 reported actions.
THE EMMES COMPANY, LLC had the largest decline in reported obligations
$6.0M→$4.7M−$1.3M
The contractor now ranks #3 by positive obligations and accounts for 8.8% of positive obligations, based on 5 reported actions.

Award activity

Buyer demand

Reported obligations through NATIONAL INSTITUTES OF HEALTH NICHD decreased
$6.3M→$4.7M−$1.6M
Latest-period activity spans 2 awards across 2 prime contractors.
How these findings are calculated

Findings are selected from matched-period changes in obligations, share, rank, funding offices, concentration, reported set-asides, material award actions, and agency-peer outliers. Related signals are combined, and only material evidence-backed changes are shown. Review the full methodology.

Funding pattern for Research and Development in Biotechnology at the Department of Health and Human Services

See how positive obligations were attributed across funding offices in the 12 months ending Jul 27, 2026.

100.0% of positive obligations were attributed to NATIONAL INSTITUTES OF HEALTH NICHD. That represents $4.7M, down $1.6M from the preceding 12 months.

Latest 12-month share of positive obligations; the gray segment represents all other reported offices.

  1. NATIONAL INSTITUTES OF HEALTH NICHD100.0% · $4.7M · down $1.6M
View reported office rankings, comparisons, and evidence

USAspending assigns each award to a funding office. That office may differ from the requiring activity, program office, contracting office, individual buyer, or actual customer.

  1. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NICHD

    #1Up 1 from #2

    Latest 12 months

    $4.7M

    100.0% of positive obligations

    Versus preceding 12 months

    −$1.6M

    2 active prime contractors · 2 awards

    View office comparison and evidence

    Reported obligations decreased 25.7% from $6.3M to $4.7M. The office’s share of positive obligations moved from 8.6% to 100.0%, a change of +91.5 percentage points.

    The latest period contains 5 actions across 2 awards. The preceding period contained 4 active prime contractors and 11 awards.

  2. Reported funding office

    NIH NIAMS

    No positive-obligation rank

    Latest 12 months

    $0

    0% of positive obligations

    Versus preceding 12 months

    +$1K

    0 active prime contractors · 0 awards

    View office comparison and evidence

    Reported obligations moved from $1K in net deobligations to $0 in net obligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 0 actions across 0 awards. The preceding period contained 1 active prime contractor and 2 awards.

  3. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NHGRI

    No positive-obligation rank

    Latest 12 months

    $0

    0% of positive obligations

    Versus preceding 12 months

    +$99

    0 active prime contractors · 0 awards

    View office comparison and evidence

    Reported obligations moved from $99 in net deobligations to $0 in net obligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 0 actions across 0 awards. The preceding period contained 1 active prime contractor and 1 award.

  4. Reported funding office

    NATIONAL INSTITUTES OF HEALTH

    No positive-obligation rank

    Latest 12 months

    −$2K

    0% of positive obligations

    Versus preceding 12 months

    +$39K

    1 active prime contractor · 1 award

    View office comparison and evidence

    Reported obligations narrowed from $41K to $2K in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 1 action across 1 award and 1 newly active prime contractor. The preceding period contained 1 active prime contractor and 1 award.

  5. Reported funding office

    FDA OFFICE OF ACQ GRANT SVCS

    No positive-obligation rank

    Latest 12 months

    −$399K

    0% of positive obligations

    Versus preceding 12 months

    −$251K

    1 active prime contractor · 1 award

    View office comparison and evidence

    Reported obligations widened from $148K to $399K in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 1 action across 1 award and 1 newly active prime contractor. The preceding period contained 1 active prime contractor and 1 award.

  6. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIAID

    No positive-obligation rank

    Latest 12 months

    −$557K

    0% of positive obligations

    Versus preceding 12 months

    −$2.2M

    24 active prime contractors · 31 awards

    View office comparison and evidence

    Reported obligations moved from $1.7M in net obligations to $557K in net deobligations. The office’s share of positive obligations moved from 2.3% to 0%, a change of −2.3 percentage points.

    The latest period contains 44 actions across 31 awards and 8 newly active prime contractors. The preceding period contained 26 active prime contractors and 56 awards.

  7. Reported funding office

    OFC ASST SEC FOR PREPARENESS RES

    No positive-obligation rank

    Latest 12 months

    −$1.4M

    0% of positive obligations

    Versus preceding 12 months

    −$759K

    1 active prime contractor · 1 award

    View office comparison and evidence

    Reported obligations widened from $621K to $1.4M in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 1 action across 1 award and 1 newly active prime contractor. The preceding period contained 1 active prime contractor and 1 award.

  8. Reported funding office

    BARDA - ASPR / DAAPPO / BARDA DCMA

    No positive-obligation rank

    Latest 12 months

    −$308.2M

    0% of positive obligations

    Versus preceding 12 months

    −$373.6M

    27 active prime contractors · 37 awards

    View office comparison and evidence

    Reported obligations moved from $65.4M in net obligations to $308.2M in net deobligations. The office’s share of positive obligations moved from 88.5% to 0%, a change of −88.5 percentage points.

    The latest period contains 48 actions across 37 awards and 16 newly active prime contractors. The preceding period contained 23 active prime contractors and 38 awards.

    Leading award-level changes

How this work is bought

Reported award structure, competition, pricing, work categories, and contracting channels for Research and Development in Biotechnology at the Department of Health and Human Services.

During Jul 28, 2025–Jul 27, 2026, this market recorded $53.4M in positive net award obligations across 12 awards. The leading reported procedure, Negotiated Proposal/Quote, accounted for 65.1% of that positive-obligation base. Awards with a reported parent IDV accounted for 9.2%.

Leading award type
90.8%
Definitive Contract
Leading reported procedure
65.1%
Negotiated Proposal/Quote
Reported parent IDV
9.2%
of positive obligations had a reported parent IDV
Median reported offers
3
12 of 12 awards reported offers

Buying method changes

Compared with Jul 28, 2024–Jul 27, 2025. Based on 12 current awards and 40 preceding awards with positive net obligations.

Median positive award obligations
$387K
Up from $125K in the preceding period
Negotiated Proposal/Quote obligation share
65.1%
Up from 54.8% in the preceding period
How to read these changes

Directional color and the Up or Down labels show historical movement only. Green does not mean favorable and red does not mean unfavorable; neither predicts a future procurement method.

View buying-method details and data coverage

Award types

Reported valueAwardsPositive obligationsShare
Definitive Contract(D)4$48.5M90.8%
Delivery Order(C)8$4.9M9.2%

Reported parent-award types

Reported valueAwardsPositive obligationsShare
IDC(B)8$4.9M9.2%
Not reported4$48.5M90.8%

Single- or multiple-award parent structure

Reported valueAwardsPositive obligationsShare
Multiple Award(M)8$4.9M9.2%
Not reported4$48.5M90.8%

Solicitation procedures

Reported valueAwardsPositive obligationsShare
Negotiated Proposal/Quote(NP)3$34.8M65.1%
Basic Research(BR)1$13.8M25.7%
Subject To Multiple Award Fair Opportunity(MAFO)8$4.9M9.2%

Extent competed

Reported valueAwardsPositive obligationsShare
Full And Open Competition(A)12$53.4M100.0%

Fair-opportunity and limited-source reporting

Reported valueAwardsPositive obligationsShare
Fair Opportunity Given(FAIR)8$4.9M9.2%
Not reported4$48.5M90.8%

Other-than-full-and-open reasons

Reported valueAwardsPositive obligationsShare
Not reported12$53.4M100.0%

Contract pricing types

Reported valueAwardsPositive obligationsShare
Cost Plus Fixed Fee(U)8$37.4M70.0%
Cost No Fee(S)4$16.0M29.9%

Product or Service Codes

Reported valueAwardsPositive obligationsShare
Health R&d Services; Health Care Services; Applied Research(AN12)3$35.0M65.5%
Health R&d Services; Health Care Services; Experimental Development(AN13)5$16.0M30.0%
Health R&d Services; Health Care Services; Basic Research(AN11)4$2.4M4.5%

Awarding subagencies

Reported valueAwardsPositive obligationsShare
Office of Assistant Secretary for Preparedness and Response(7505)7$46.1M86.3%
National Institutes of Health(7529)5$7.3M13.7%

Awarding offices

Reported valueAwardsPositive obligationsShare
Barda - Aspr / Daappo / Barda Dcma(75A501)7$46.1M86.3%
National Institutes Of Health Nichd(75N940)1$4.7M8.8%
National Institutes Of Health Niaid(75N930)4$2.6M4.9%

Reported parent IDVs

Reported valueAwardsPositive obligationsShare
HHSO100201500004I(7505)1$2.2M4.1%
HHSN272201700040I(7529)2$1.9M3.6%
HHSN272201700032I(7529)1$387K0.73%
HHSN272201300012I(7529)1$318K0.60%
HHSO100201700011I(7505)3$89K0.17%
Not reported4$48.5M90.8%

Exactly matched vehicle usage

4 awards matched an unambiguous catalog vehicle PIID. Company membership is not used as evidence of award-channel usage.

Offers, award size, and timing

Median reported offers
3 median
12 reported · 0 not reported
Positive award obligations
$387K median
$63K–$2.2M middle 50%
Reported performance period
3,094 days (~8.5 years) median
12 reported · 0 not reported

Calculations group latest-period actions by award, retain awards with positive net obligations for share denominators, and use each award's latest reported USAspending procurement fields as of Jul 27, 2026. Blank competition, pricing, PSC, or parent-IDV values remain not reported; they are not inferred. Offer counts must be positive and below the FPDS 999 placeholder. Awarding organizations can differ from the funding agency that defines this page.

Prime contractors for Research and Development in Biotechnology at the Department of Health and Human Services

Latest 12-month concentration and complete prime contractor rankings across the period shown.

Prime contractor concentration
2 of 8prime contractors account for at least 80% of positive obligations in the last 12 months
Largest prime contractor
56.3%of positive obligations in the last 12 months
Leading four prime contractors
95.0%of positive obligations in the last 12 months
Leading eight prime contractors
100.0%of positive obligations in the last 12 months

Based on $53.3M in positive obligations during the 12 months ending Jul 27, 2026. Individual shares and movement appear in the searchable rankings below. Movement compares with Jul 28, 2024–Jul 27, 2025.

Last 12mo obligation volume: Highest positive obligations first; net deobligations follow by magnitude; contractors with no activity in the last 12 months follow by all-period obligations. Ranks use the complete contractor list and remain fixed when search narrows the results.

15 leading contractors
  1. #1

    Last 12mo obligations

    $30.0M

    56.3%

    Dollar movement

    −$19.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
    Obligations: prior → latest
    $49.9M → $30.0M
    −39.8%
    Share: prior → latest
    48.9% → 56.3%
    +7.4 percentage points
    All-period obligations
    $279.2M
    40.2% of all-period positive obligations · 4 awards
    Recorded activity
    Since Nov 18, 2021
    through Aug 29, 2025

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside12
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  2. #2

    Last 12mo obligations

    $13.8M

    25.8%

    Dollar movement

    −$23.0M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for HOFFMANN-LA ROCHE INC.
    Obligations: prior → latest
    $36.8M → $13.8M
    −62.6%
    Share: prior → latest
    36.0% → 25.8%
    −10.2 percentage points
    All-period obligations
    $62.6M
    9.0% of all-period positive obligations · 1 award
    Recorded activity
    Since Jun 1, 2022
    through Sep 25, 2025

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  3. #3

    Last 12mo obligations

    $4.7M

    8.8%

    Dollar movement

    −$1.3M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    5 actions

    Historical and award details for THE EMMES COMPANY, LLC
    Obligations: prior → latest
    $6.0M → $4.7M
    −21.9%
    Share: prior → latest
    5.9% → 8.8%
    +2.9 percentage points
    All-period obligations
    $33.0M
    4.8% of all-period positive obligations · 9 awards
    Recorded activity
    Since Nov 18, 2021
    through Jul 20, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported10
    Reported small business21
    All-period set-aside types

    None reported.

  4. #4

    Last 12mo obligations

    $2.1M

    4.0%

    Dollar movement

    −$609K

    vs. prior 12 months

    Last 12mo awards

    9 awards

    13 actions

    Historical and award details for BATTELLE MEMORIAL INSTITUTE
    Obligations: prior → latest
    $2.8M → $2.1M
    −22.1%
    Share: prior → latest
    2.7% → 4.0%
    +1.3 percentage points
    All-period obligations
    $11.3M
    1.6% of all-period positive obligations · 34 awards
    Recorded activity
    Since Oct 5, 2021
    through May 12, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported913
    Reported small business00
    All-period set-aside types

    None reported.

  5. #5

    Last 12mo obligations

    $1.9M

    3.6%

    Dollar movement

    +$2.4M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    6 actions

    Historical and award details for UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
    Obligations: prior → latest
    −$489K → $1.9M
    Not comparable
    Share: prior → latest
    0% → 3.6%
    +3.6 percentage points
    All-period obligations
    $8.5M
    1.2% of all-period positive obligations · 17 awards
    Recorded activity
    Since Nov 2, 2021
    through May 18, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported28
    Reported small business00
    All-period set-aside types

    None reported.

  6. #6

    Last 12mo obligations

    $387K

    0.73%

    Dollar movement

    −$29K

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for TRUSTEES OF TUFTS COLLEGE
    Obligations: prior → latest
    $416K → $387K
    −7.0%
    Share: prior → latest
    0.41% → 0.73%
    +0.3 percentage points
    All-period obligations
    $1.3M
    0.19% of all-period positive obligations · 4 awards
    Recorded activity
    Since Dec 21, 2021
    through May 7, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported12
    Reported small business00
    All-period set-aside types

    None reported.

  7. #7

    Last 12mo obligations

    $310K

    0.58%

    Dollar movement

    −$670K

    vs. prior 12 months

    Last 12mo awards

    2 awards

    3 actions

    Historical and award details for UNIVERSITY OF ALABAMA AT BIRMINGHAM
    Obligations: prior → latest
    $980K → $310K
    −68.4%
    Share: prior → latest
    0.96% → 0.58%
    −0.4 percentage points
    All-period obligations
    $3.2M
    0.47% of all-period positive obligations · 10 awards
    Recorded activity
    Since Nov 24, 2021
    through Apr 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported22
    Reported small business00
    All-period set-aside types

    None reported.

  8. #8

    Last 12mo obligations

    $63K

    0.12%

    Dollar movement

    +$63K

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for INBIOS INTERNATIONAL INC
    Obligations: prior → latest
    $0 → $63K
    Not comparable
    Share: prior → latest
    0% → 0.12%
    +0.1 percentage points
    All-period obligations
    $2.2M
    0.32% of all-period positive obligations · 2 awards
    Recorded activity
    Since Oct 22, 2021
    through Sep 8, 2025

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  9. #9

    Last 12mo obligations

    −$332.0M

    0%

    Dollar movement

    −$332.0M

    vs. prior 12 months

    Last 12mo awards

    3 awards

    3 actions

    Historical and award details for REGENERON PHARMACEUTICALS INC
    Obligations: prior → latest
    $0 → −$332.0M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$5.6M
    0% of all-period positive obligations · 3 awards
    Recorded activity
    Since Jun 30, 2022
    through Mar 19, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside32
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  10. #10

    Last 12mo obligations

    −$12.5M

    0%

    Dollar movement

    −$12.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for AVITA MEDICAL AMERICAS, LLC
    Obligations: prior → latest
    $0 → −$12.5M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$12.5M
    0% of all-period positive obligations · 1 award
    Recorded activity
    Since Nov 30, 2021
    through Feb 12, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside10
    Reported no set-aside00
    Not reported00
    Reported small business10
    All-period set-aside types
    • 1 · Total small business
  11. #11

    Last 12mo obligations

    −$2.6M

    0%

    Dollar movement

    −$2.6M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for PFIZER INC
    Obligations: prior → latest
    $0 → −$2.6M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$2.7M
    0% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 6, 2023
    through May 12, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  12. #12

    Last 12mo obligations

    −$2.5M

    0%

    Dollar movement

    −$2.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for NOVARTIS PHARMACEUTICALS CORPORATION
    Obligations: prior → latest
    $0 → −$2.5M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$14.0M
    0% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 13, 2022
    through Jul 8, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  13. #13

    Last 12mo obligations

    −$2.0M

    0%

    Dollar movement

    −$2.0M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for ALTASCIENCES PRECLINICAL SEATTLE LLC
    Obligations: prior → latest
    $0 → −$2.0M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$2.0M
    0% of all-period positive obligations · 1 award
    Recorded activity
    Since Jul 21, 2026
    through Jul 21, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported10
    Reported small business00
    All-period set-aside types

    None reported.

  14. #14

    Last 12mo obligations

    −$1.5M

    0%

    Dollar movement

    −$1.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for ATOX BIO LTD
    Obligations: prior → latest
    $0 → −$1.5M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$1.5M
    0% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 8, 2025
    through Sep 8, 2025

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  15. #15

    Last 12mo obligations

    −$1.1M

    0%

    Dollar movement

    −$1.1M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    2 actions

    Historical and award details for ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
    Obligations: prior → latest
    $0 → −$1.1M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$2.3M
    0% of all-period positive obligations · 6 awards
    Recorded activity
    Since Dec 15, 2021
    through Sep 24, 2025

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported20
    Reported small business20
    All-period set-aside types

    None reported.

Recompete watch for Research and Development in Biotechnology at the Department of Health and Human Services

Investigate potential recompetes surfaced by near-term end dates, award value, and recent contract changes.

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.

EO14042 EMERGENT AV7909 ANTHRAX VACCINE

The reported potential end date is Sep 29, 2026. Current award value is 96.7% of reported potential value ($1.4B of $1.4B).

Performance period

98.2%

As of Jul 27, 2026Potential end Sep 29, 2026

Current award value as a share of potential value

96.7%

$1.4B current$1.4B potential
Supporting data

Reported performance starts Sep 30, 2016.

No later potential end date is reported; current and potential end dates are both Sep 29, 2026.

$1.4B is obligated against $1.4B in current reported award value (100.0%).

Reported potential end dates: May 31, 2025 → Aug 31, 2025 → Sep 29, 2026.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201600030C

CERUS CORPORATION

EXTEND THE BASE (CLIN 0001) AND OPTION 1 (CLIN 0002) PERIOD OF PERFORMANCE THROUGH 31 MARCH 2027 TO ALLOW COMPLETION OF THE REMAINING EFFORT WITHOUT INCREASING THE CONTRACT VALUE. TRANSFER GOVERNMENT-FURNISHED EQUIPMENT (GFE) FROM CONTRACT HHSO100201

$185.2M is obligated on an award with a reported potential end date of March 31, 2027.

Performance period

93.7%

As of Jul 27, 2026Potential end Mar 31, 2027

Current award value as a share of potential value

70.0%

$197.5M current$282.2M potential
Supporting data

Reported performance starts Jun 17, 2016.

No later potential end date is reported; current and potential end dates are both Mar 31, 2027.

$185.2M is obligated against $197.5M in current reported award value (93.8%).

Reported potential end dates: Dec 31, 2023 → Dec 31, 2025 → Sep 30, 2026 → Mar 31, 2027.

THE PURPOSE OF THIS MODIFICATION: 1. NO COST EXTENSION FOR OPTION 01 (CLIN 0002), 2. REVISE KEY PERSONNEL, AND 3. REVISE THE STATEMENT OF WORK.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201600009C

DNAE GROUP HOLDINGS LIMITED

DNAE / PATHOGEN IDENTIFICATION FROM SPECIMEN, VIA CAPTURE, EXTRACTION AND SEQUENCING (PISCES)

The reported potential end date is Dec 31, 2026. Current award value is 70.1% of reported potential value ($43.4M of $61.9M).

Performance period

95.8%

As of Jul 27, 2026Potential end Dec 31, 2026

Current award value as a share of potential value

70.1%

$43.4M current$61.9M potential
Supporting data

Reported performance starts Sep 28, 2016.

No later potential end date is reported; current and potential end dates are both Dec 31, 2026.

$43.4M is obligated against $43.4M in current reported award value (100.0%).

Reported potential end dates: May 31, 2023 → Sep 15, 2023 → Dec 31, 2024 → Jan 31, 2025 → Dec 31, 2025 → Dec 31, 2026.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201600017C

REGENERON PHARMACEUTICALS INC

NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.4 AND F.4

$693.1M is obligated on an award with a reported potential end date of September 29, 2027.

Performance period

88.2%

As of Jul 27, 2026Potential end Sep 29, 2027

Current award value as a share of potential value

91.6%

$693.1M current$756.4M potential
Supporting data

Reported performance starts Sep 30, 2017.

No later potential end date is reported; current and potential end dates are both Sep 29, 2027.

$693.1M is obligated against $693.1M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201700016C

MERCK SHARP & DOHME LLC

MERCK - EBOLA ZAIRE VACCINE EXERCISE AND FUND OPTION 6 IN ORDER TO CONTINUE TO MEET THE REQUIREMENT OF MAINTAINING 1.13 MILLION DOSES OF ERVEBO.

$236.3M is obligated on an award with a reported potential end date of September 27, 2027.

Performance period

88.3%

As of Jul 27, 2026Potential end Sep 27, 2027

Current award value as a share of potential value

81.1%

$236.3M current$291.4M potential
Supporting data

Reported performance starts Sep 28, 2017.

No later potential end date is reported; current and potential end dates are both Sep 27, 2027.

$236.3M is obligated against $236.3M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201700012C

HOFFMANN-LA ROCHE INC.

THE PURPOSE OF THIS MODIFICATION IS ADD SUPPLEMENTAL FUNDING FOR CLIN 0001 & 0002 AND TO UPDATED THE PERIOD OF PERFORMANCE (POP) FOR CLIN 0001 TO END ON 12/31/2026.

$175.7M is obligated on an award with a reported potential end date of September 30, 2027.

Performance period

89.3%

As of Jul 27, 2026Potential end Sep 30, 2027

Current award value as a share of potential value

69.8%

$175.7M current$251.7M potential
Supporting data

Reported performance starts Sep 15, 2016.

No later potential end date is reported; current and potential end dates are both Sep 30, 2027.

$175.7M is obligated against $175.7M in current reported award value (100.0%).

Reported potential end dates: Sep 30, 2024 → Sep 30, 2025 → Dec 31, 2026 → Sep 30, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201600038C

These are research leads, not confirmed recompetes. USAspending records through Jul 27, 2026; reported dates and values can change through later modifications.

Award activity for Research and Development in Biotechnology at the Department of Health and Human Services

Recent contract actions with unusually large obligation changes or meaningful shifts in contractor and funding-office activity.

Deobligation

This action

−$331.7M

REGENERON PHARMACEUTICALS INC

BARDA - ASPR / DAAPPO / BARDA DCMA

E.O. RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING. DESCOPE MOD IAW WITH RTWS TO REMOVE UNUSED FUNDS FROM MULTIPLE CLINS RESULTING IN A DE-OBLIGATION OF $331,708,160.10 AND A REDUCTION IN TOTAL CONTRACT VALUE OF $331,708,160.10.

Why it stands out

This award recorded a material contraction.

The action removed $331.7M. A deobligation does not by itself show lower requirement demand.

Award net obligations
$279.6M
Share of 12-month positive obligations
622.5%
Supporting data
Prime contractor
0% share
$332.0M net decline; action accounted for 99.9%
Funding office
0% attributed share
−88.5 percentage points · $373.6M net decline; action accounted for 88.8%
Related:Largest net deobligationLargest deobligation action
PIID HHSO100201700020C · Mod P00016
Deobligation

This action

−$12.5M

AVITA MEDICAL AMERICAS, LLC

BARDA - ASPR / DAAPPO / BARDA DCMA

AUTOGRAFT-SPARING PRODUCTS FOR DEFINITIVE CARE OF BURN INJURIES

Why it stands out

This award recorded a material contraction.

The action removed $12.5M. A deobligation does not by itself show lower requirement demand.

Award net obligations
$40.8M
Share of 12-month positive obligations
23.5%
Supporting data
Prime contractor
0% share
$12.5M net decline; action accounted for 100.0%
PIID HHSO100201500028C · Mod P00017
Deobligation

This action

−$1.4M

PFIZER INC

OFC ASST SEC FOR PREPARENESS RES

THE PURPOSE OF MODIFICATION P00014 IS TO DE-OBLIGATE CANCELING FUNDS

Why it stands out

This award recorded a material contraction.

The action removed $1.4M. A deobligation does not by itself show lower requirement demand.

Award net obligations
$68.4M
Share of 12-month positive obligations
2.6%
Supporting data
Prime contractor
0% share
$2.6M net decline; action accounted for 52.8%
Funding office
0% attributed share
$759K net decline; action exceeded it by $621K
PIID HHSO100201500029C · Mod P00014
Deobligation

This action

−$2.5M

NOVARTIS PHARMACEUTICALS CORPORATION

BARDA - ASPR / DAAPPO / BARDA DCMA

THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE CANCELLING FUNDS IN THE AMOUNT OF $2,539,496.23 AS FOLLOWS: 1. $1,050,656.17 FROM CLIN 0013 2. $1,488,840.00 FROM CLIN 0014 3. $0.06 FROM CLIN 0012

Why it stands out

This award recorded a material contraction.

The action removed $2.5M. A deobligation does not by itself show lower requirement demand.

Award net obligations
$16.3M
Share of 12-month positive obligations
4.8%
Supporting data
Prime contractor
0% share
$2.5M net decline; action accounted for 100.0%
PIID HHSO100201700026C · Mod P00013
Modification

This action

+$30.0M

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.

BARDA - ASPR / DAAPPO / BARDA DCMA

EO14042 EMERGENT AV7909 ANTHRAX VACCINE

Why it stands out

One action equaled at least half of the market’s latest 12-month positive obligations.

The $30.0M action represented 56.3% of the market’s positive obligations over the latest 12 months.

Award net obligations
$1.4B
Share of 12-month positive obligations
56.3%
Supporting data
Prime contractor
#1 · 56.3% share
$19.9M net decline despite this positive action
Funding office
0% attributed share
$373.6M net decline despite this positive action
Related:Unusually large action
PIID HHSO100201600030C · Mod P00020
Modification

This action

+$13.8M

HOFFMANN-LA ROCHE INC.

BARDA - ASPR / DAAPPO / BARDA DCMA

THE PURPOSE OF THIS MODIFICATION IS ADD SUPPLEMENTAL FUNDING FOR CLIN 0001 & 0002 AND TO UPDATED THE PERIOD OF PERFORMANCE (POP) FOR CLIN 0001 TO END ON 12/31/2026.

Why it stands out

One action equaled at least a quarter of the market’s latest 12-month positive obligations.

The $13.8M action represented 25.8% of the market’s positive obligations over the latest 12 months.

Award net obligations
$175.7M
Share of 12-month positive obligations
25.8%
Supporting data
Prime contractor
#2 · 25.8% share
$23.0M net decline despite this positive action
Funding office
0% attributed share
$373.6M net decline despite this positive action
PIID HHSO100201600038C · Mod P00016
View recent award activity by date (10)
  1. ALTASCIENCES PRECLINICAL SEATTLE LLCDeobligation · PIID HHSO10033001T
    Action−$2.0M
    Award net obligations$4.2M
  2. SEATTLE CHILDREN'S HOSPITALDeobligation · PIID HHSN272201700059C
    Action−$55
    Award net obligations$24.7M
  3. NOVARTIS PHARMACEUTICALS CORPORATIONDeobligation · PIID HHSO100201700026C
    Action−$2.5M
    Award net obligations$16.3M
  4. TRANSNETYX, INCDeobligation · PIID 75N98B21F00007
    Action−$7
    Award net obligations$5K
  5. TRANSNETYX, INCDeobligation · PIID 75N98B21F00008
    Action−$597
    Award net obligations$18K
  6. TRANSNETYX, INCDeobligation · PIID 75N98021F00001
    Action−$11
    Award net obligations$20K
  7. THE EMMES COMPANY, LLCModification · PIID HHSN275201700002C
    Action+$4.7M
    Award net obligations$66.0M
  8. UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTONModification · PIID 75N93024F00002
    Action+$1.7M
    Award net obligations$3.3M
  9. CHIMERIX, INC.Deobligation · PIID HHSO100201100013C
    Action−$614K
    Award net obligations$77.1M
  10. CERUS CORPORATIONDeobligation · PIID HHSO100201600009C
    Action−$280K
    Award net obligations$185.2M

Apply this research to a live pursuit

Sweetspot connects opportunity qualification, competitive research, capture, and proposal work in one workspace.

See Sweetspot in action

Related market research

Complete market indexes:

Same NAICS at other agencies:

Nearby NAICS at this agency:

Markets sharing leading prime records:

Leading-prime vehicle memberships:

Company memberships do not establish award-channel use.

Reported obligations include contract actions from October 1, 2021 through July 27, 2026. Set-aside and business-size fields reflect award records, not a contractor's current eligibility.

Review data methodology